AbbVie price target raised to $280 from $260 at JPMorgan
JPMorgan raised the firm's price target on AbbVie to $280 from $260 and keeps an Overweight rating on the shares. The firm, which is anticipating "a largely in-line quarter," continues to see "modest upside" to guidance through 2026, the analyst tells investors in a preview.
JPMorgan raised the firm's price target on AbbVie to $280 from $260 and keeps an Overweight rating on the shares. The firm, which is anticipating "a largely in-line quarter," continues to see "modest upside" to guidance through 2026, the analyst tells investors in a preview.